PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : A61K 9/20	A1	(11) International Publication Number: WO 00/32172
		(43) International Publication Date: 8 June 2000 (08.06.00)

(21) International Application Number: PCT/JP99/06602

(22) International Filing Date: 26 November 1999 (26.11.99)

(30) Priority Data:

10/353966	27 November 1998 (27.11.98)	JP
11/266433	21 September 1999 (21.09.99)	JP

(71)(72) Applicant and Inventor: TAKADA, Kanji [JP/JP]; 618–2, Gokoumachidori Gojoagaru Azuchi–cho, Shimogyo–ku, Kyoto–shi, Kyoto 600–8040 (JP).

(74) Agents: IMAMURA, Masazumi et al.; KRF Building, 5th Floor, 5–5, Kyobashi 1–chome, Chuo–ku, Tokyo 104–0031 (JP).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: AN ORAL FORMULATION FOR GASTROINTESTINAL DRUG DELIVERY

(57) Abstract

An oral formulation for gastrointestinal drug delivery which comprises an adhesion site–controlling layer for attaching the formulation to the selected site in the digestive tract, a drug–carrying layer for containing a drug and an adhesive and a protecting layer for protecting the drug in the drug–carrying layer, wherein the drug–carrying layer exists between the protecting layer and the adhesion site–controlling layer, and the adhesion site–controlling layer may attach to the protecting layer. The formulation can improve bioavailability of drugs which have low bioavailability.